Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 25, 2026
Why Is Zscaler (ZS) Stock Down -8.24% Today?

Why Is Zscaler (ZS) Stock Down -8.24% Today?

Key Takeaways

  • Shares of Zscaler dropped 8.24% in Friday's session, falling to $196.95 from a prior close of $214.64.
  • The primary catalyst was an executive leadership change: Chief Revenue Officer Mike Rich is stepping down for personal reasons, effective October 1.
  • Investor caution was compounded by profit-taking after a strong run, with the stock having climbed roughly 14% in September.
  • Analysts broadly framed the transition as low-disruption, noting the successor was promoted internally and that the company reaffirmed its fiscal 2027 guidance.
  • Traders are watching the upcoming Analyst Day in early October and the next earnings report for clarity on sales momentum and growth trajectory.

Opening Summary

Zscaler, Inc. (ZS), a leading cloud-native cybersecurity provider best known for its Zero Trust Exchange platform, saw its stock sell off sharply in Friday's trading. The shares declined 8.24%, closing at $196.95 versus a prior-session close of $214.64. The move extended a decline that began in after-hours trading on Thursday after the company announced a change at the top of its revenue organization. Markets attributed the drop primarily to the departure of Chief Revenue Officer Mike Rich for personal reasons, a shift that reignited concerns about execution and sales leadership stability at the high-growth software firm.

Catalyst Breakdown: Chief Revenue Officer Departure

The dominant driver behind the decline was Zscaler's announcement that Mike Rich, who has led the company's revenue organization since joining in November 2023, is stepping down from the Chief Revenue Officer role for personal reasons. Rich will remain with the company as a strategic advisor through December 31, 2026, to support the transition.

Zscaler named Ross Tackett as his successor, effective October 1, 2026. Tackett has served as the company's Head of Worldwide Sales for the past three years and brings more than three decades of technology sales leadership experience, including prior senior roles at ServiceNow and Dell. He will oversee global revenue operations, the sales organization, the strategic partner ecosystem, and go-to-market execution.

Despite the internal, well-established nature of the succession, the abrupt timing rattled investors. Any change in sales leadership at a company still rebuilding its go-to-market engine tends to raise questions about pipeline continuity and revenue visibility. CEO Jay Chaudhry emphasized Tackett's "operational discipline, global scale, and customer-first leadership," but the market initially treated the news as a reason to lock in gains.

Secondary Driver: Profit-Taking After a Strong September Run

The sell-off was amplified by the stock's recent momentum. ZS had rallied roughly 14% through September before this decline, leaving shares vulnerable to a pullback on any negative headline. With the stock trading at a premium valuation relative to its slowing growth outlook, even modest uncertainty around the sales organization was enough to trigger profit-taking among short-term holders.

Analyst Reaction: A "Low-Disruption" Transition

Several Wall Street analysts sought to calm investor concerns, framing the leadership change as manageable rather than destabilizing. Analysts at Jefferies acknowledged some near-term execution risk given the timing of the departure but said they expect limited disruption, noting that Tackett helped develop the current sales strategy and brings extensive experience. Rosenblatt Securities described the move as a "low-disruption" transition, pointing to the internal promotion and the multi-month handoff period as factors supporting business continuity. Guggenheim's John DiFucci, meanwhile, highlighted Rich's role in shifting Zscaler toward a more account-centric sales model.

Market Context and Trading Activity

The decline unfolded against a backdrop in which Zscaler investors were already sensitive to execution risk. In early September, the company reported a strong fiscal fourth quarter but issued fiscal 2027 guidance pointing to materially slower revenue and annual recurring revenue growth of roughly 16.6% to 17.5%, alongside an AI-focused restructuring that includes a roughly 3% workforce reduction. That prior guidance reset left the stock with less room for additional uncertainty.

Trading activity reflected the news-driven nature of the move, with volume running well above the lighter levels seen in recent sessions as sellers moved in. The decline was stock-specific rather than a broad sector event: while Zscaler's peers in cybersecurity have faced similar investor scrutiny around decelerating growth, Friday's drop was tied directly to the company's own leadership announcement rather than a wider market or sector selloff.

What Comes Next for ZS

Looking ahead, investors will focus on how smoothly the sales leadership transition proceeds and whether it affects Zscaler's ability to hit its reaffirmed fiscal 2027 targets. Key events on the horizon include the company's Analyst Day on October 6—its first in five years—where management is expected to address the long-term AI security opportunity, the sales-force transition, and the path back toward faster annual recurring revenue growth. The next earnings release is anticipated around early December.

Risks include the possibility that the transition disrupts deal momentum during a critical first-half renewal period, as well as broader questions about whether the company can re-accelerate growth while rebuilding its sales engine. The departure of a senior revenue leader so soon after a conservative guidance reset keeps execution squarely in focus, and ZS shares may remain volatile until investors gain clearer visibility into the sales organization's stability.

Trending AI Robots

For traders seeking a data-driven edge in navigating volatile names like Zscaler, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading tools. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches that align with their own objectives. Explore the Trending AI Robots to discover which strategies are currently outperforming.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ZS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ZS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ZS moved above the 200-day moving average on September 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on ZS as a result. In 66 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for ZS just turned positive on September 15, 2026. Looking at past instances where ZS's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.

Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZS advanced for three days, in 264 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 155 of 235 cases where ZS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ZS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.477) is normal, around the industry mean (20.511). P/E Ratio (0.000) is within average values for comparable stocks, (160.845). Projected Growth (PEG Ratio) (2.199) is also within normal values, averaging (3.691). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (9.158) is also within normal values, averaging (103.889).

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Block Inc (NYSE:XYZ), Twilio (NYSE:TWLO), NetApp (NASDAQ:NTAP), Okta (NASDAQ:OKTA), Zscaler (NASDAQ:ZS), MongoDB (NASDAQ:MDB).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.38B. The market cap for tickers in the group ranges from 48.8K to 3.72T. MSFT holds the highest valuation in this group at 3.72T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 28%. LHSW experienced the highest price growth at 50%, while HUBC experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -9%. For the same stocks of the Industry, the average monthly volume growth was 25% and the average quarterly volume growth was -16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 70
Price Growth Rating: 55
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
ZS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an antivirus & cloud security platform

Industry ComputerCommunications

Industry
Packaged Software
Address
120 Holger Way
Phone
+1 408 533-0288
Employees
8700
Web
https://www.zscaler.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.